HeartFlow was founded in 2007 by Charles Taylor and Christopher Zarins. Throughout 2021 and 2022, HeartFlow has taken significant steps towards going the public, ultimately deciding to terminate a $2.4 billion SPAC deal in February 2022, citing "current unfavorable market conditions." This is only one recent example of a medical technology company encountering challenges in the SPAC process. These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
According to Fierce Biotech, "HeartFlow is developing a test for coronary artery disease that uses deep learning artificial intelligence algorithms to analyze coronary CT angiograms." In March 2022, the company announced that John Farquhar – the former COO, president, and board member – has been appointed CEO. HeartFlow has raised over $530 million in funding from investors including Panorama Point Partners, Wellington Management, Rancilio Cube, and Martis Capital. As of the last funding round, which brought in over $240 million, HeartFlow has arrived at a post-money valuation of $1.5 billion.
HeartFlow does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.
The stock price for HeartFlow will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 6/13/2019 | Series E | $1.65B | $XXX.XX | $XXX.XX |
| 5/10/2016 | Series D | $801.13MM | $XXX.XX | $XXX.XX |
| 2/26/2014 | Series C | $400.5MM | $XXX.XX | $XXX.XX |
| 2/4/2011 | Series B-1 and B-2 | $120MM | $XXX.XX | $XXX.XX |
| 4/16/2010 | Series A | $6.5MM | $XXX.XX | $XXX.XX |
HeartFlow is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own HeartFlow pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
HeartFlow is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
